HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.08 – $2.19
Volume10,757
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.34M
Price / earnings
—
Price / book
-5.08×
Price / sales
2,287.26×
EV / sales
3,170.51×
EV / EBITDA
-1.52×
Profitability
Earnings per share
-$2.06
Return on assets
-274.52%
Return on equity
504.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.98×
Current ratio
0.14×
Quick ratio
0.07×
Cash ratio
0.01×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HSCS, quarterly periods
Line item
Q1 FY2027 Jul 31, 2026
Q4 FY2026 Apr 30, 2026
Q3 FY2026 Jan 31, 2026
Q2 FY2026 Oct 31, 2025
Q1 FY2026 Jul 31, 2025
Q4 FY2025 Apr 30, 2025
Q3 FY2025 Jan 31, 2025
Q2 FY2025 Oct 31, 2024
Revenue
$2.1K
$0
$0
$2.42K
$1.9K
$4.35K
$0
$0
Cost of revenue
$760
$0
$0
$1.01K
$760
$1.88K
$0
$0
Gross profit
$1.34K
$0
$0
$1.41K
$1.14K
$2.47K
$0
$0
Selling, general and administrative
$2.03M
$2.06M
$1.29M
$1.35M
$878.05K
$993.78K
$1.34M
$786.07K
Research and development
$906.63K
$476.21K
$638.58K
$727.03K
$997.21K
$929.09K
$1.03M
$1.2M
Total operating expenses
$2.94M
$2.54M
$1.93M
$2.07M
$1.88M
$1.92M
$2.37M
$1.99M
Operating income
-$2.94M
-$2.54M
-$1.93M
-$2.07M
-$1.87M
-$1.92M
-$2.37M
-$1.99M
Interest expense
-$235.26K
-$228.31K
-$61.51K
-$279.53K
-$183.69K
-$180.85K
-$179.48K
-$117.6K
Income before taxes
-$3.17M
-$2.75M
-$1.99M
-$2.35M
-$2.05M
-$2.09M
-$2.54M
-$2.08M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.17M
-$2.75M
-$1.99M
-$2.35M
-$2.05M
-$2.09M
-$2.54M
-$2.08M
Net income attributable to common shareholders
-$3.17M
-$2.75M
-$1.99M
-$2.35M
-$2.05M
-$2.09M
-$2.54M
-$2.08M
EBITDA
-$2.93M
-$2.53M
-$1.92M
-$2.07M
-$1.87M
-$1.91M
-$2.37M
-$1.97M
Basic earnings per share
-$0.86
-$0.85
-$0.63
-$0.85
-$1.58
-$1.95
-$2.57
-$2.27
Diluted earnings per share
-$0.86
-$0.85
-$0.63
-$0.85
-$1.58
-$1.95
-$2.57
-$2.27
Recent news
Company coverage with links to the original publishers.
Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.
HeartSciences Inc. (HSCS) reported a quarterly loss of $0.86 per share, missing the consensus estimate of $0.78 loss by 10.26%. The company posted zero revenues, missing estimates by 97.9%. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Medical Info Systems industry ranks in the top 34% of Zacks industries.
HeartSciences Inc. will host an Investor Webinar and present at the Emerging Growth Conference 85 on August 20, 2025, to provide updates on their AI-powered medical technology for ECG/EKG analysis.
HeartSciences, an AI-powered medical technology company, announced its first commercial customer for the MyoVista Insights platform, Westcliffe Health Innovations in the U.K. This partnership aims to enhance ECG management and improve healthcare efficiency.
HeartSciences, an AI-powered medical technology company, has launched the MyoVista Insights platform, a cloud-native ECG management system designed to enhance clinical decision-making and healthcare IT efficiency. The platform features AI-ECG algorithms, streamlined workflows, and advanced cybersecurity.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.